Login to Your Account

'This is very, very difficult'

After hours of trying to get their minds around mismatched study results and data that didn't lend themselves to the questions the FDA was asking, members of the Arthritis Advisory Committee voted 10-5 Monday to recommend approval of a 2-mg dose of Eli Lilly and Co.'s baricitinib, while rejecting a 4-mg dose in a reverse vote of 5-10.

more »

Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.



Partners in Focus